#STOLENCOLON REPLACEMENTS MAKE THEIR DEBUT IN KANSAS CITY AND NEW YORK CITY

NEXT STORY
Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies
PREV STORY
RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa

AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) --  XBiotech Inc. (NASDAQ: XBIT) announced today ...

author_avatar
NASDAQ Market News

Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today ...

author_avatar
NASDAQ Market News

Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week

author_avatar
NASDAQ Market News